普罗布考联合瑞舒伐他汀对缺血性脑卒中患者内皮细胞功能及血清铁调素25水平的影响

Effect of Probucol Combined with Rosuvastatin on Endothelial Cell Function and Serum Hepcidin-25 Levels in Patients with Ischemic Stroke

目的:探讨普罗布考联合瑞舒伐他汀对缺血性脑卒中(IS)患者内皮细胞功能和血清铁调素25(Hepc25)水平的影响。方法:选取2020年5月~2023年4月期间于某院就诊的130例IS患者作为研究对象,采用随机数字表法分为对照组和观察组,每组65例。根据患者病情给予调整血压、降低体温、维持呼吸、控糖、溶栓、抗凝血、抗血小板、神经保护、降低颅内压等常规治疗,对照组患者在常规治疗基础上加用瑞舒伐他汀钙片,观察组患者在对照组治疗基础上加用普罗布考片,两组均持续治疗6个月。比较两组患者临床疗效、神经功能[美国国立卫生研究院卒中量表(NIHSS)、Barthel指数(BI)和蒙特利尔认知评估量表(MoCA)]、内皮细胞功能[血管内皮生长因子(VEGF)、基质细胞衍生因子-1α(SDF-1α)、血管生成素(Ang)和血小板衍生生长因子(PDGF)]、血清Hepc25水平及不良反应发生情况。结果:治疗后,观察组患者治疗总有效率(93.85%)高于对照组(73.85%,P<0.05);两组患者NIHSS评分和血清Hepc25水平均降低,且观察组低于对照组(P<0.05);BI、MoCA评分和VEGF、SDF-1α、Ang、PDGF水平均升高,且观察组高于对照组(P<0.05)。治疗期间,两组患者不良反应总发生率比较无统计学差异(P>0.05)。结论:在常规治疗基础上,普罗布考联合瑞舒伐他汀治疗IS患者临床疗效较佳,可有效改善IS患者病情,提高内皮细胞功能,降低血清Hepc25水平,且未增加不良反应的发生风险。

Objective:To investigate the effects of probucol combined with rosuvastatin on endothelial cell function and serum hepcidin-25(Hepc25)level in patients with ischemic stroke(IS).Methods:A total of 130 patients with IS who were treated in a hospital from May 2020 to April 2023 were selected and divided into control group and observation group by random number table method,with 65 patients in each group.The patients were given conventional treatment based on their conditions,including blood pressure management,temperature control,respiration support,glucose control,thrombolysis,anticoagulation,antiplatelet therapy,neuroprotection and intracranial pressure control.The control group was given rosuvastatin calcium tablets in addition to the conventional treatment,and the observation group was given probucol tablets in addition to the treatment received by the control group.Both groups were treated for 6 months.The clinical efficacy,neurological function[National Institute of Health stroke scale(NIHSS),Barthel index(BI)and Montreal cognitive assessment(MoCA)],endothelial cell function[vascular endothelial growth factor(VEGF),stromal cell-derived factor-1α(SDF-1α),angiopoietin(Ang)and platelet-derived growth factor(PDGF)],serum Hepc25 levels and the incidence of adverse reactions were compared between the two groups.Results:Following treatment,the overall treatment effectiveness in the observation group(93.85%)was higher than that of the control group(73.85%,P<0.05).The NIHSS scores and serum Hepc25 level were decreased in both groups,and the observation group were lower than those in the control group(P<0.05).BI,MoCA scores,and the levels of VEGF,SDF-1α,Ang and PDGF were increased in both groups,and the observation group were higher than those in the control group(P<0.05).No statistically significant difference was observed in the overall incidence of adverse reactions during the treatment period between the two groups(P>0.05).Conclusion:Probucol in combination with rosuvastatin demonstrated significant clinical efficacy in the treatment of IS patients when added to the conventional treatment.This combined treatment can effectively improve the condition of IS patients and the function of endothelial cells,reduce the serum Hepc25 levels,and does not increase the risk of adverse reactions.